Patents by Inventor Guillaume Wettstein

Guillaume Wettstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240016807
    Abstract: The invention relates to a drug combination and a method for the treatment of a liver disease, the combination comprising lanifibranor and firsocostat.
    Type: Application
    Filed: November 16, 2021
    Publication date: January 18, 2024
    Inventors: Guillaume WETTSTEIN, Pierre BROQUA
  • Patent number: 11504380
    Abstract: The invention relates to a method of treating cirrhosis which comprises administering to a subject in need thereof lanifibranor or a deuterated derivative thereof.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 22, 2022
    Assignee: INVENTIVA
    Inventors: Guillaume Wettstein, Pierre Broqua, Jean-Louis Junien
  • Publication number: 20210137937
    Abstract: The invention relates to a method of treating cirrhosis which comprises administering to a subject in need thereof lanifibranor or a deuterated derivative thereof.
    Type: Application
    Filed: November 8, 2019
    Publication date: May 13, 2021
    Inventors: Guillaume WETTSTEIN, Pierre BROQUA, Jean-Louis JUNIEN
  • Patent number: 9326993
    Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: May 3, 2016
    Assignee: ONCOGENEX TECHNOLOGIES INC.
    Inventors: Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein
  • Publication number: 20150126584
    Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 17, 2014
    Publication date: May 7, 2015
    Inventors: Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein
  • Patent number: 8987223
    Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: March 24, 2015
    Assignee: Oncogenex Technologies Inc.
    Inventors: Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein
  • Publication number: 20120294846
    Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 14, 2012
    Publication date: November 22, 2012
    Applicant: ONCOGENEX TECHNOLOGIES INC.
    Inventors: Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein